Adrixetinib

Adrixetinib (Q702) is an Axl/Mer/CSF1R protein tyrosine kinase inhibitor with antineoplastic activity[1][2].

Product Specifications

CAS Number

[2394874-66-7]

Product Name Alternative

Q702

UNSPSC

12352005

Target

C-Fms; TAM Receptor

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/adrixetinib.html

Purity

99.51

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C1=NN(CCC)C=C1OCC(F)(F)F)NC2=NC=C(C=C2)OC3=C4C=C(OC)C(OC)=CC4=NC=C3

Molecular Formula

C25H24F3N5O5

Molecular Weight

531.48

References & Citations

[1]WHO Drug Informat ion - World Health Organization (WHO) .|[2]Nam Kiyean, et al. Quinoline derivatives as inhibitors of Axl/Mer RTK and CSF1R and their preparation: World Intellectual Property Organization, WO2019229251. 2019-12-05.|[3]WHO Drug Information-World Health Organization (WHO) .